TheracosBio Announces Commercial Availability of Brenzavvy (bexagliflozin) for the Treatment of…
TheracosBio announced that Brenzavvy (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, is now available by prescription through the Mark Cuban Cost…
Read More...
Read More...
